| Species |
Human |
| Protein Construction |
ANGPTL3/Angiopoietin-like 3 (Ser17-Lys219)
Accession # Q9Y5C1 |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized ANGPTL3/Angiopoietin-like 3, His & Avi, Human at 1μg/ml (100μl/Well) can bind AntiANGPTL3 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
26.6 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 30-38 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
ANGPTL3 is a secreted glycoprotein that is structurally related to the angiopoietins. Mature human ANGPTL3 contains an N-terminal coiled coil domain and a C‑terminal fibrinogen-like domain. ANGPTL3 is expressed in the liver from early in development through adulthood. Acts in part as a hepatokine that is involved in regulation of lipid and glucose metabolism. Proposed to play a role in the trafficking of energy substrates to either storage or oxidative tissues in response to food intake. |
| Synonyms |
ANGPTL3; ANGPT5; ANG-5; Angiopoietin-5; FHBL2; ANL3; Angiopoietin-5; Angiopoietin-like Protein 3 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
